BR112015013071A2 - solução de trombina e seus métodos de uso - Google Patents

solução de trombina e seus métodos de uso

Info

Publication number
BR112015013071A2
BR112015013071A2 BR112015013071A BR112015013071A BR112015013071A2 BR 112015013071 A2 BR112015013071 A2 BR 112015013071A2 BR 112015013071 A BR112015013071 A BR 112015013071A BR 112015013071 A BR112015013071 A BR 112015013071A BR 112015013071 A2 BR112015013071 A2 BR 112015013071A2
Authority
BR
Brazil
Prior art keywords
methods
thrombin solution
thrombin
lyophilization
solution
Prior art date
Application number
BR112015013071A
Other languages
English (en)
Other versions
BR112015013071A8 (pt
BR112015013071B1 (pt
Inventor
Nur Israel
Bar Liliana
BELYAEV Oleg
Meidler Roberto
Original Assignee
Omrix Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omrix Biopharmaceuticals Ltd filed Critical Omrix Biopharmaceuticals Ltd
Publication of BR112015013071A2 publication Critical patent/BR112015013071A2/pt
Publication of BR112015013071A8 publication Critical patent/BR112015013071A8/pt
Publication of BR112015013071B1 publication Critical patent/BR112015013071B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)

Abstract

resumo patente de invenção: "solução de trombina e seus métodos de uso". a invenção refere-se a métodos para a liofilização de uma solução de trombina aquosa, soluções de trombina para uso nesses métodos de liofilização e composições de trombina sólida produzidas por meio de tais métodos.
BR112015013071-2A 2012-12-03 2013-11-28 Solução de trombina aquosa, e seu método para liofilização BR112015013071B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL223396 2012-12-03
IL22339612 2012-12-03
US201361753542P 2013-01-17 2013-01-17
US61/753,542 2013-01-17
PCT/IL2013/000088 WO2014087394A1 (en) 2012-12-03 2013-11-28 Thrombin solution and methods of use thereof

Publications (3)

Publication Number Publication Date
BR112015013071A2 true BR112015013071A2 (pt) 2017-07-11
BR112015013071A8 BR112015013071A8 (pt) 2019-10-08
BR112015013071B1 BR112015013071B1 (pt) 2023-01-17

Family

ID=50825810

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122022012099-7A BR122022012099B1 (pt) 2012-12-03 2013-11-28 Composição de trombina sólida
BR112015013071-2A BR112015013071B1 (pt) 2012-12-03 2013-11-28 Solução de trombina aquosa, e seu método para liofilização

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122022012099-7A BR122022012099B1 (pt) 2012-12-03 2013-11-28 Composição de trombina sólida

Country Status (14)

Country Link
US (4) US9212357B2 (pt)
EP (2) EP2925347B1 (pt)
JP (2) JP6526565B2 (pt)
KR (1) KR102101611B1 (pt)
CN (2) CN110251468A (pt)
AU (1) AU2013353636B2 (pt)
BR (2) BR122022012099B1 (pt)
CA (1) CA2892083A1 (pt)
HK (1) HK1214958A1 (pt)
IL (1) IL239043B (pt)
MX (1) MX358132B (pt)
PL (1) PL2925347T3 (pt)
RU (1) RU2670956C9 (pt)
WO (1) WO2014087394A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
TW201702385A (zh) * 2015-03-13 2017-01-16 崇謹 孫 穩定凝血酶之方法及其組合物
US10159720B2 (en) 2015-12-08 2018-12-25 Omrix Biopharmaceuticals Ltd Thrombin microcapsules, preparation and uses thereof
IL242984A0 (en) * 2015-12-08 2016-02-29 Omrix Biopharmaceuticals Ltd Thrombin microcapsules, their preparation and how to use them
US10420134B2 (en) 2016-02-02 2019-09-17 Cisco Technology, Inc. System and method to facilitate subframe scheduling in a split medium access control radio access network environment
CN109010906B (zh) * 2018-08-16 2021-05-14 陈明远 一种促进术后伤口局部止血及促进术后创面上皮化的生物胶水及其工作方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JP2715104B2 (ja) * 1988-08-18 1998-02-18 株式会社ミドリ十字 トロンビン乾燥製剤
DE3843126C3 (de) 1988-12-22 1994-10-06 Octapharma Ag Verfahren zur Herstellung eines hochreinen Thrombinkonzentrates
JP3905921B2 (ja) 1992-10-02 2007-04-18 ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー 凝固第▲ｖｉｉｉ▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法
CN1100655A (zh) * 1992-11-19 1995-03-29 迟斌元 一种含有缓冲剂和凝血酶的药物组合物
JP3028274B2 (ja) * 1994-09-30 2000-04-04 持田製薬株式会社 トロンビン固形製剤の安定化方法
GB9503750D0 (en) 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
JPWO2004043503A1 (ja) * 2002-11-14 2006-03-09 財団法人化学及血清療法研究所 トロンビン固定化生体吸収性合成不織布
WO2006009989A1 (en) * 2004-06-22 2006-01-26 Zymogenetics, Inc. Thrombin compositions
EP1927658B1 (en) 2004-06-22 2012-10-10 Zymogenetics, Inc. Thrombin compositions
ES2226587B1 (es) * 2004-10-22 2005-12-16 Probitas Pharma, S.A. Composicion de trombina estable.
EP2377554A1 (en) * 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
CN101282908A (zh) * 2005-09-05 2008-10-08 兰贝克赛实验室有限公司 制备冻干的碳酸氢钠的方法
PL2097068T3 (pl) 2006-11-24 2013-12-31 Cadila Healthcare Ltd Preparaty koniugatów PEG-interferon alfa
RU2464015C2 (ru) * 2006-12-15 2012-10-20 Лайфбонд Лтд. Желатин-трансглутаминазные кровоостанавливающие повязки и изолирующие средства
CN101214374A (zh) * 2007-01-05 2008-07-09 兆科药业（合肥）有限公司 具有促凝血与止血功能的制剂
ES2421642T3 (es) * 2008-03-03 2013-09-04 Omrix Biopharmaceuticals Ltd Una esponja de gelatina que comprende un ingrediente activo, su preparación y uso
ES2438491T3 (es) * 2008-09-22 2014-01-17 Omrix Biopharmaceuticals Ltd. Dispositivo implantable que comprende un sustrato pre-recubierto con fibrina estabilizada
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
CA2796729C (en) 2010-04-20 2020-06-23 Octapharma Ag Melezitose for stabilizing human blood plasma proteins
CN102917691A (zh) * 2010-06-01 2013-02-06 巴克斯特国际公司 用于生产干燥、稳定的止血组合物的方法
IL207586A0 (en) 2010-08-12 2010-12-30 Omrix Biopharmaceuticals Ltd A fibrin based therapeutic preparation and use thereof
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof

Also Published As

Publication number Publication date
EP2925347A1 (en) 2015-10-07
MX2015006986A (es) 2015-09-23
IL239043B (en) 2020-09-30
AU2013353636A1 (en) 2015-07-16
CN110251468A (zh) 2019-09-20
BR112015013071A8 (pt) 2019-10-08
US20220098570A1 (en) 2022-03-31
JP6526565B2 (ja) 2019-06-05
RU2015126540A (ru) 2017-01-13
MX358132B (es) 2018-08-06
KR20150091503A (ko) 2015-08-11
US9212357B2 (en) 2015-12-15
US20140154773A1 (en) 2014-06-05
CA2892083A1 (en) 2014-06-12
US11993797B2 (en) 2024-05-28
BR112015013071B1 (pt) 2023-01-17
US20200032239A1 (en) 2020-01-30
US20160060614A1 (en) 2016-03-03
IL239043A0 (en) 2015-07-30
EP3760221A1 (en) 2021-01-06
US10479987B2 (en) 2019-11-19
AU2013353636B2 (en) 2018-03-01
BR122022012099B1 (pt) 2023-01-24
HK1214958A1 (zh) 2016-08-12
JP2016505543A (ja) 2016-02-25
US11225652B2 (en) 2022-01-18
RU2670956C9 (ru) 2018-11-21
RU2670956C2 (ru) 2018-10-26
CN104822387A (zh) 2015-08-05
JP2018162254A (ja) 2018-10-18
EP2925347B1 (en) 2020-08-26
PL2925347T3 (pl) 2020-12-28
WO2014087394A1 (en) 2014-06-12
KR102101611B1 (ko) 2020-04-20

Similar Documents

Publication Publication Date Title
UY34811A (es) Compuestos y composiciones para inhibir la actividad de la abl1, abl2 y bcr-abl1
CL2016001547A1 (es) Composiciones para el cuidado oral
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
BR112015013071A2 (pt) solução de trombina e seus métodos de uso
WO2015028969A3 (en) Transduction buffer
GT201400111A (es) Triazolopiridinas sustituidas
CL2013000322A1 (es) Compuestos derivados de piperidina sustituida; proceso de preparacion; composicion farmaceutica y su uso para producir un efecto antiproliferativo y/o proapoptotico.
TR201909788T4 (tr) C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
BR112015001344A2 (pt) xilose isomerases e seus usos
BR112015013124A2 (pt) novos derivados de piridina
BR112015006426A2 (pt) composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, proteína e baixos níveis de eletrólitos
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
EA201590887A1 (ru) Композиция
BR112015009600A2 (pt) piridina-2-amidas úteis como agonistas cb2
PH12015502118A1 (en) Pyridin-4-yl derivatives
BR112014011254A2 (pt) 2-tiopirimidinonas
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
BR112014002940A2 (pt) uso e composição agroquímica de dibutilamidas de ácido carboxílico
TR201903565T4 (tr) Yara iyileşmesi için yöntemler ve bileşimler.
BR112015028824A2 (pt) composição de tensoativo concentrada
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
CO6990738A2 (es) Agentes de reversion anticoagulante

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/11/2013, OBSERVADAS AS CONDICOES LEGAIS